Connor, Clark & Lunn Investment Management Ltd. Pacira Bio Sciences, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $18.8 Billion
- Q3 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 80,533 shares of PCRX stock, worth $1.57 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
80,533Holding current value
$1.57 Million% of portfolio
0.01%Shares
7 transactions
Others Institutions Holding PCRX
# of Institutions
263Shares Held
50.4MCall Options Held
429KPut Options Held
391K-
Black Rock Inc. New York, NY8.01MShares$156 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.3MShares$103 Million0.0% of portfolio
-
Pacer Advisors, Inc. Malvern, PA4.96MShares$96.6 Million0.18% of portfolio
-
State Street Corp Boston, MA2.01MShares$39.2 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.98MShares$38.5 Million0.05% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $892M
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...